Loading...
Header Logo
Keywords
Last Name
Institution

Professor Sima Rafati

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mou Z, Li J, Boussoffara T, Kishi H, Hamana H, Ezzati P, Hu C, Yi W, Liu D, Khadem F, Okwor I, Jia P, Shitaoka K, Wang S, Ndao M, Petersen C, Chen J, Rafati S, Louzir H, Muraguchi A, Wilkins JA, Uzonna JE. Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells. Sci Transl Med. 2015 Oct 21; 7(310):310ra167. PMID: 26491077.
      View in: PubMed
    2. Golshani M, Rafati S, Jahanian-Najafabadi A, Nejati-Moheimani M, Siadat SD, Shahcheraghi F, Bouzari S. In silico design, cloning and high level expression of L7/L12-TOmp31 fusion protein of Brucella antigens. Res Pharm Sci. 2015 Sep-Oct; 10(5):436-45. PMID: 26752992; PMCID: PMC4691964.
    3. Rafati S, Kamhawi S, Valenzuela JG, Ghanei M. Building Research and Development Capacity for Neglected Tropical Diseases Impacting Leishmaniasis in the Middle East and North Africa: A Case Study. PLoS Negl Trop Dis. 2015 Aug; 9(8):e0003695. PMID: 26313269; PMCID: PMC4551800.
    4. Sadeghi S, Seyed N, Etemadzadeh MH, Abediankenari S, Rafati S, Taheri T. In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite. Korean J Parasitol. 2015 Aug; 53(4):385-94. PMID: 26323836; PMCID: PMC4566512.
    5. Katebi A, Gholami E, Taheri T, Zahedifard F, Habibzadeh S, Taslimi Y, Shokri F, Papadopoulou B, Kamhawi S, Valenzuela JG, Rafati S. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model. Mol Immunol. 2015 Oct; 67(2 Pt B):501-11. PMID: 26298575.
      View in: PubMed
    6. Shahbazi M, Zahedifard F, Taheri T, Taslimi Y, Jamshidi S, Shirian S, Mahdavi N, Hassankhani M, Daneshbod Y, Zarkesh-Esfahani SH, Papadopoulou B, Rafati S. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis. PLoS One. 2015; 10(7):e0132794. PMID: 26197085; PMCID: PMC4509652.
    7. Shahbazi M, Zahedifard F, Saljoughian N, Doroud D, Jamshidi S, Mahdavi N, Shirian S, Daneshbod Y, Hamid Zarkesh-Esfahani S, Papadopoulou B, Rafati S. Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis. Vet Parasitol. 2015 Sep 15; 212(3-4):130-9. PMID: 26255093.
      View in: PubMed
    8. Hosseini M, Haji Fatahaliha M, Aghebati-Maleki L, Movassagh Pour A, Rafati S, Seifi-Najmi M, Younesi V, Jadidi-Niaragh F, Yousefi M. Recombinant Leishmania major lipophosphoglycan 3 activates human T-lymphocytes via TLR2-independent pathway. J Immunotoxicol. 2016; 13(2):263-9. PMID: 26181511.
      View in: PubMed
    9. Golshani M, Rafati S, Siadat SD, Nejati-Moheimani M, Shahcheraghi F, Arsang A, Bouzari S. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen. Mol Immunol. 2015 Aug; 66(2):384-91. PMID: 25968974.
      View in: PubMed
    10. Golshani M, Rafati S, Dashti A, Gholami E, Siadat SD, Oloomi M, Jafari A, Bouzari S. Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice. Mol Immunol. 2015 Jun; 65(2):287-92. PMID: 25723468.
      View in: PubMed
    11. Oliveira PR, Dessein H, Romano A, Cabantous S, de Brito ME, Santoro F, Pitta MG, Pereira V, Pontes-de-Carvalho LC, Rodrigues V, Rafati S, Argiro L, Dessein AJ. IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis. J Immunol. 2015 Mar 15; 194(6):2664-72. PMID: 25672756.
      View in: PubMed
    12. Taheri T, Saberi Nik H, Seyed N, Doustdari F, Etemadzadeh MH, Torkashvand F, Rafati S. Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity. Exp Parasitol. 2015 Mar; 150:44-55. PMID: 25637784.
      View in: PubMed
    13. Pishraft-Sabet L, Kosinska AD, Rafati S, Bolhassani A, Taheri T, Memarnejadian A, Alavian SM, Roggendorf M, Samimi-Rad K. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96. Arch Virol. 2015 Jan; 160(1):141-52. PMID: 25348271.
      View in: PubMed
    14. Pishraft Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, Alavian SM, Rafati S, Samimi Rad K. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat Mon. 2014 Oct; 14(10):e22215. PMID: 25419219; PMCID: PMC4238154.
    15. Seyed N, Taheri T, Vauchy C, Dosset M, Godet Y, Eslamifar A, Sharifi I, Adotevi O, Borg C, Rohrlich PS, Rafati S. Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine. PLoS One. 2014; 9(10):e108848. PMID: 25310094; PMCID: PMC4195657.
    16. Fotouhi F, Farahmand B, Heidarchi B, Esghaei M, Rafati S, Tavassoti Kheiri M. In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein. Jundishapur J Microbiol. 2014 Sep; 7(9):e11812. PMID: 25485058; PMCID: PMC4255373.
    17. Saljoughian N, Taheri T, Rafati S. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis. Front Immunol. 2014; 5:134. PMID: 24744757; PMCID: PMC3978289.
    18. Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N, Torkashvand F, Meneses C, Papadopoulou B, Kamhawi S, Valenzuela JG, Rafati S. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. PLoS Negl Trop Dis. 2014 Mar; 8(3):e2751. PMID: 24675711; PMCID: PMC3967951.
    19. Saljoughian N, Zahedifard F, Doroud D, Doustdari F, Vasei M, Papadopoulou B, Rafati S. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Parasite Immunol. 2013 Dec; 35(12):397-408. PMID: 23710803.
      View in: PubMed
    20. Dabirian S, Taslimi Y, Zahedifard F, Gholami E, Doustdari F, Motamedirad M, Khatami S, Azadmanesh K, Nylen S, Rafati S. Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate. PLoS Negl Trop Dis. 2013; 7(10):e2491. PMID: 24147170; PMCID: PMC3798388.
    21. Mohit E, Rafati S. Biological delivery approaches for gene therapy: strategies to potentiate efficacy and enhance specificity. Mol Immunol. 2013 Dec; 56(4):599-611. PMID: 23911418.
      View in: PubMed
    22. Saljoughian N, Taheri T, Zahedifard F, Taslimi Y, Doustdari F, Bolhassani A, Doroud D, Azizi H, Heidari K, Vasei M, Namvar Asl N, Papadopoulou B, Rafati S. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis. 2013; 7(4):e2174. PMID: 23638195; PMCID: PMC3630202.
    23. Hosseinzadeh S, Bolhassani A, Rafati S, Taheri T, Zahedifard F, Daemi A, Taslimi Y, Hashemi M, Memarnejadian A. A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. Drug Deliv. 2013 Apr-May; 20(3-4):190-8. PMID: 23745741.
      View in: PubMed
    24. Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A, Rafati S. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. Immunotherapy. 2012 Nov; 4(11):1107-20. PMID: 23194361.
      View in: PubMed
    25. Bolhassani A, Rafati S. Mini-chaperones: potential immuno-stimulators in vaccine design. Hum Vaccin Immunother. 2013 Jan; 9(1):153-61. PMID: 23108356; PMCID: PMC3667931.
    26. Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model. Immunol Lett. 2012 Dec 17; 148(2):117-25. PMID: 23085605.
      View in: PubMed
    27. Mohit E, Bolhassani A, Zahedifard F, Seyed N, Eslamifar A, Taghikhani M, Samimi-Rad K, Rafati S. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. Mol Immunol. 2013 Jan; 53(1-2):149-60. PMID: 22926003.
      View in: PubMed
    28. Mohit E, Rafati S. Chemokine-based immunotherapy: delivery systems and combination therapies. Immunotherapy. 2012 Aug; 4(8):807-40. PMID: 22947009.
      View in: PubMed
    29. Stäger S, Rafati S. CD8(+) T cells in leishmania infections: friends or foes? Front Immunol. 2012; 3:5. PMID: 22566891; PMCID: PMC3342007.
    30. Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL?/6 mouse model. Scand J Immunol. 2012 Jan; 75(1):27-37. PMID: 21916914.
      View in: PubMed
    31. Doroud D, Rafati S. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Rev Vaccines. 2012 Jan; 11(1):69-86. PMID: 22149710.
      View in: PubMed
    32. Mehrizi AA, Zakeri S, Rafati S, Salmanian AH, Djadid ND. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies. Parasite Immunol. 2011 Nov; 33(11):594-608. PMID: 21883290.
      View in: PubMed
    33. Safaiyan S, Bolhassani A, Nylen S, Akuffo H, Rafati S. Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection. Parasite Immunol. 2011 Nov; 33(11):609-20. PMID: 21793857.
      View in: PubMed
    34. Seyed N, Zahedifard F, Safaiyan S, Gholami E, Doustdari F, Azadmanesh K, Mirzaei M, Saeedi Eslami N, Khadem Sadegh A, Eslami Far A, Sharifi I, Rafati S. In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. PLoS Negl Trop Dis. 2011 Sep; 5(9):e1295. PMID: 21909442; PMCID: PMC3167772.
    35. McDowell MA, Rafati S, Ramalho-Ortigao M, Ben Salah A. Leishmaniasis: Middle East and North Africa research and development priorities. PLoS Negl Trop Dis. 2011 Jul; 5(7):e1219. PMID: 21814585; PMCID: PMC3144177.
    36. Doroud D, Zahedifard F, Vatanara A, Taslimi Y, Vahabpour R, Torkashvand F, Vaziri B, Rouholamini Najafabadi A, Rafati S. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl Trop Dis. 2011 Jul; 5(7):e1236. PMID: 21765963; PMCID: PMC3134432.
    37. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol. 2011 Jun; 33(6):335-48. PMID: 21410716.
      View in: PubMed
    38. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, Vahabpour R, Torkashvand F, Vaziri B, Rafati S. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release. 2011 Jul 30; 153(2):154-62. PMID: 21530597.
      View in: PubMed
    39. Mizbani A, Taslimi Y, Zahedifard F, Taheri T, Rafati S. Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae. Parasitol Res. 2011 Sep; 109(3):793-9. PMID: 21442256.
      View in: PubMed
    40. Bolhassani A, Gholami E, Zahedifard F, Moradin N, Parsi P, Doustdari F, Seyed N, Papadopoulou B, Rafati S. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. Exp Parasitol. 2011 May; 128(1):9-17. PMID: 21276444.
      View in: PubMed
    41. Amani J, Mousavi SL, Rafati S, Salmanian AH. Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice. Plant Sci. 2011 Apr; 180(4):620-7. PMID: 21421410.
      View in: PubMed
    42. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer. 2011 Jan 07; 10:3. PMID: 21211062; PMCID: PMC3024302.
    43. Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol. 2011 Mar; 127(3):627-36. PMID: 21187087.
      View in: PubMed
    44. Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, Seyed N, Torkashvand F, Vaziri B, Rafati S. Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol. 2011 Mar; 127(3):637-45. PMID: 21187086.
      View in: PubMed
    45. Doroud D, Vatanara A, Zahedifard F, Gholami E, Vahabpour R, Najafabadi AR, Rafati S. Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Control Release. 2010 Nov 20; 148(1):e105-6. PMID: 21529578.
      View in: PubMed
    46. Amani J, Salmanian AH, Rafati S, Mousavi SL. Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine. 2010 Oct 04; 28(42):6923-9. PMID: 20709010.
      View in: PubMed
    47. Taheri T, Salmanian AH, Gholami E, Doustdari F, Zahedifard F, Rafati S. Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity. Exp Parasitol. 2010 Oct; 126(2):135-45. PMID: 20417202.
      View in: PubMed
    48. Doroud D, Vatanara A, Zahedifard F, Gholami E, Vahabpour R, Rouholamini Najafabadi A, Rafati S. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Pharm Pharm Sci. 2010; 13(3):320-35. PMID: 21092706.
      View in: PubMed
    49. Amani J, Mousavi SL, Rafati S, Salmanian AH. In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. Theor Biol Med Model. 2009 Dec 08; 6:28. PMID: 19995413; PMCID: PMC3224939.
    50. Bolhassani A, Zahedifard F, Taslimi Y, Taghikhani M, Nahavandian B, Rafati S. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients. Indian J Med Res. 2009 Nov; 130(5):533-41. PMID: 20090101.
      View in: PubMed
    51. Arashkia A, Roohvand F, Memarnejadian A, Aghasadeghi MR, Rafati S. Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes. 2010 Feb; 40(1):44-52. PMID: 19882243.
      View in: PubMed
    52. Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin. 2009 Oct; 5(10):671-89. PMID: 19684468.
      View in: PubMed
    53. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine. 2009 Dec 10; 28(1):53-62. PMID: 19818721.
      View in: PubMed
    54. Azizi H, Hassani K, Taslimi Y, Najafabadi HS, Papadopoulou B, Rafati S. Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. Parasitology. 2009 Jun; 136(7):723-35. PMID: 19416551.
      View in: PubMed
    55. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv. 2009 May; 16(4):196-204. PMID: 19514980.
      View in: PubMed
    56. Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA. Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett. 2009; 16(7):842-50. PMID: 19601916.
      View in: PubMed
    57. Abtahi H, Salmanian AH, Rafati S, Nejad GB, Saffari M, Ghazavi A, Mosayebi G. The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene. Pak J Biol Sci. 2008 Nov 01; 11(21):2472-7. PMID: 19205266.
      View in: PubMed
    58. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines. 2008 Oct; 7(8):1185-99. PMID: 18844593.
      View in: PubMed
    59. Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine. 2008 Oct 29; 26(46):5822-9. PMID: 18804512.
      View in: PubMed
    60. Salhi A, Rodrigues V, Santoro F, Dessein H, Romano A, Castellano LR, Sertorio M, Rafati S, Chevillard C, Prata A, Alcaïs A, Argiro L, Dessein A. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 2008 May 01; 180(9):6139-48. PMID: 18424735.
      View in: PubMed
    61. Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine. 2008 Jun 19; 26(26):3362-70. PMID: 18471945.
      View in: PubMed
    62. Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp Parasitol. 2008 Mar; 118(3):393-401. PMID: 18093586.
      View in: PubMed
    63. Golkar M, Rafati S, Abdel-Latif MS, Brenier-Pinchart MP, Fricker-Hidalgo H, Sima BK, Babaie J, Pelloux H, Cesbron-Delauw MF, Mercier C. The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women. Diagn Microbiol Infect Dis. 2007 Aug; 58(4):419-26. PMID: 17509806.
      View in: PubMed
    64. Balenga NA, Rafati S. Innate immune system: specific or non-specific? Med Hypotheses. 2007; 69(2):460-1. PMID: 17482763.
      View in: PubMed
    65. Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine. 2007 May 22; 25(21):4159-69. PMID: 17395340.
      View in: PubMed
    66. Golkar M, Shokrgozar MA, Rafati S, Musset K, Assmar M, Sadaie R, Cesbron-Delauw MF, Mercier C. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine. 2007 May 22; 25(21):4301-11. PMID: 17418457.
      View in: PubMed
    67. Rafati S, Hassani N, Taslimi Y, Movassagh H, Rochette A, Papadopoulou B. Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. Clin Vaccine Immunol. 2006 Oct; 13(10):1104-10. PMID: 17028214; PMCID: PMC1595312.
    68. Balenga NA, Zahedifard F, Weiss R, Sarbolouki MN, Thalhamer J, Rafati S. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J Biotechnol. 2006 Jul 25; 124(3):602-14. PMID: 16515817.
      View in: PubMed
    69. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006 Mar; 123(3):423-38. PMID: 16778321.
      View in: PubMed
    70. Rafati S, Ghaemimanesh F, Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice. Vaccine. 2006 Apr 12; 24(16):3290-7. PMID: 16481076.
      View in: PubMed
    71. Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine. 2006 Mar 15; 24(12):2169-75. PMID: 16325969.
      View in: PubMed
    72. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine. 2005 May 25; 23(28):3716-25. PMID: 15882533.
      View in: PubMed
    73. Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine. 2004 May 07; 22(15-16):1930-40. PMID: 15121305.
      View in: PubMed
    74. Rafati S, Salmanian AH, Taheri T, Masina S, Schaff C, Taslimi Y, Fasel N. Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis. Mol Biochem Parasitol. 2004 May; 135(1):13-20. PMID: 15287582.
      View in: PubMed
    75. Nakhaee A, Taheri T, Taghikhani M, Mohebali M, Salmanian AH, Fasel N, Rafati S. Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population. Vet Parasitol. 2004 Jan 30; 119(2-3):107-23. PMID: 14746971.
      View in: PubMed
    76. Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, Emamjomeh M, Hejazi H, Modabber F. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol. 2003 Nov; 134(2):303-8. PMID: 14616791; PMCID: PMC1808866.
    77. Farzaneh P, Ebtekar M, Hassan ZM, Rafati S. Murine cytokine patterns following rubella vaccination. Iran J Allergy Asthma Immunol. 2003 Jun; 2(2):89-93. PMID: 17301362.
      View in: PubMed
    78. Pascalis H, Lavergne A, Bourreau E, Prévot-Linguet G, Kariminia A, Pradinaud R, Rafati S, Launois P. Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun. 2003 May; 71(5):2924-6. PMID: 12704171; PMCID: PMC153268.
    79. Rafati S, Nakhaee A, Taheri T, Ghashghaii A, Salmanian AH, Jimenez M, Mohebali M, Masina S, Fasel N. Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Exp Parasitol. 2003 Mar-Apr; 103(3-4):143-51. PMID: 12880591.
      View in: PubMed
    80. Rafati S, Kariminia A, Seyde-Eslami S, Narimani M, Taheri T, Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. Vaccine. 2002 Jun 07; 20(19-20):2439-47. PMID: 12057598.
      View in: PubMed
    81. Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 2001 May 14; 19(25-26):3369-75. PMID: 11348700.
      View in: PubMed
    82. Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N. Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol. 2001 Mar; 113(1):35-43. PMID: 11254952.
      View in: PubMed
    83. Rafati S, Baba AA, Bakhshayesh M, Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin Exp Immunol. 2000 Apr; 120(1):134-8. PMID: 10759774; PMCID: PMC1905606.
    84. Solioz N, Blum-Tirouvanziam U, Jacquet R, Rafati S, Corradin G, Mauël J, Fasel N. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 1999 Dec 10; 18(9-10):850-9. PMID: 10580198.
      View in: PubMed
    85. Rafati S, Couty-Jouve S, Alimohammadian MH, Louis JA. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. Clin Exp Immunol. 1997 Nov; 110(2):203-11. PMID: 9367403; PMCID: PMC2265498.
    Rafati's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description